Similar articles

• Ticarcillin-clavulanate therapy for infections with ticarcillin-resistant microorganisms.

  Gelfand MS, Lawson RD, Baucom W. Gelfand MS, et al. South Med J. 1989 Apr;82(4):433-7. doi: 10.1097/00007611-198904000-00007. South Med J. 1989. PMID: 2705069
• Bactericidal effects of ticarcillin-clavulanic acid against beta-lactamase-producing bacteria in vivo.

  Boon RJ, Beale AS, Sutherland R. Boon RJ, et al. Antimicrob Agents Chemother. 1986 May;29(5):838-44. doi: 10.1128/AAC.29.5.838. Antimicrob Agents Chemother. 1986. PMID: 3524431 Free PMC article.
• Ticarcillin-clavulanic acid therapy in severe infections.

  Van der Auwera P, Legrand JC. Van der Auwera P, et al. Drugs Exp Clin Res. 1985;11(11):805-13. Drugs Exp Clin Res. 1985. PMID: 3836862
• [Current antimicrobial agent series II: Ticarcillin].

  Ueda Y. Ueda Y. Jpn J Antibiot. 1988 Jul;41(7):761-81. Jpn J Antibiot. 1988. PMID: 3050182 Review. Japanese. No abstract available.
• Rational prescribing of extended-spectrum penicillin beta-lactamase inhibitor combinations: focus on ticarcillin/clavulanic acid.

  Reed MD. Reed MD. Ann Pharmacother. 1998 Jan;32(1):S17-21. doi: 10.1177/106002809803200105. Ann Pharmacother. 1998. PMID: 9475835 Review.